Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Navicixizumab |
Trade Name | |
Synonyms | OMP-305B83|OMP 305B83|OMP305B83 |
Drug Descriptions |
Navicixizumab (OMP-305B83) is a bispecific antibody that binds both DLL4 and VEGF, which inhibits NOTCH and VEGFR signaling and may prevent angiogenesis and tumor growth (PMID: 30229512). |
DrugClasses | DLL4 Antibody 7 VEGF Antibody 12 |
CAS Registry Number | 1638338-43-8 |
NCIT ID | C119620 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Fluorouracil + Irinotecan + Leucovorin + Navicixizumab | Fluorouracil Irinotecan Leucovorin Navicixizumab | 0 | 1 |
Irinotecan + Navicixizumab | Irinotecan Navicixizumab | 0 | 1 |
Navicixizumab | Navicixizumab | 0 | 2 |
Navicixizumab + Paclitaxel | Navicixizumab Paclitaxel | 0 | 2 |